ImmunityBio (NASDAQ:IBRX - Free Report) had its target price increased by Piper Sandler from $5.00 to $6.00 in a report published on Monday, Benzinga reports. Piper Sandler currently has a neutral rating on the stock.
ImmunityBio Stock Performance
Shares of NASDAQ:IBRX traded up $1.64 during mid-day trading on Monday, hitting $8.99. The stock had a trading volume of 66,044,522 shares, compared to its average volume of 5,670,063. The company's 50 day moving average is $5.34 and its 200-day moving average is $4.28. ImmunityBio has a 12-month low of $1.25 and a 12-month high of $10.53. The company has a market cap of $6.09 billion, a PE ratio of -7.75 and a beta of 1.23.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last released its earnings results on Tuesday, March 19th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.01). The firm had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.03 million. On average, equities research analysts predict that ImmunityBio will post -0.68 EPS for the current fiscal year.
Institutional Trading of ImmunityBio
Several institutional investors have recently made changes to their positions in IBRX. SG Americas Securities LLC acquired a new stake in ImmunityBio in the 3rd quarter valued at approximately $57,000. Exchange Traded Concepts LLC increased its holdings in ImmunityBio by 22.3% during the 3rd quarter. Exchange Traded Concepts LLC now owns 58,136 shares of the company's stock worth $98,000 after purchasing an additional 10,596 shares in the last quarter. Aire Advisors LLC bought a new stake in shares of ImmunityBio in the third quarter valued at about $25,000. Stonehage Fleming Financial Services Holdings Ltd acquired a new position in shares of ImmunityBio during the third quarter worth about $144,000. Finally, Merit Financial Group LLC grew its holdings in shares of ImmunityBio by 84.0% during the third quarter. Merit Financial Group LLC now owns 43,800 shares of the company's stock worth $74,000 after buying an additional 20,000 shares in the last quarter. 8.58% of the stock is currently owned by institutional investors and hedge funds.
About ImmunityBio
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies.
Featured Articles
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
